Page 40 - ARNM-1-1

Advances in Radiotherapy
& Nuclear Medicine SIR-spheres Y-90 resin microspheres for HCC treatment

Southern and Central Vietnam: Experience of a large tertiary https://doi.org/10.1055/s-0030-1247132
referral center, 2010 to 2016. World J Hepatol, 10: 116–123.
14. Do SH, 2015, Epidemiology of hepatitis B and C virus
https://doi.org/10.4254/wjh.v10.i1.116 infections and liver cancer in Vietnam. Euroasian J
Hepatogastroenterol, 5: 49–51.
4. Couri T, Pillai A, 2019, Goals and targets for personalized
therapy for HCC. Hepatol Int, 13: 125–137. https://doi.org/10.5005/jp-journals-10018-1130
https://doi.org/10.1007/s12072-018-9919-1 15. Le VQ, Nguyen VH, Nguyen VH, et al., 2019, Epidemiological
characteristics of advanced hepatocellular carcinoma in the
5. Rognoni C, Ciani O, Sommariva S, et al., 2017, Real-world northern region of Vietnam. Cancer Control, 26.
data for the evaluation of transarterial radioembolization
versus sorafenib in hepatocellular carcinoma: A cost- https://doi.org/10.1177/1073274819862793
effectiveness analysis. Value Health, 20: 336–344. 16. Salem R, Gabr A, Riaz A, et al., 2018, Institutional decision
https://doi.org/10.1016/j.jval.2016.09.2397 to adopt Y90 as primary treatment for hepatocellular
carcinoma informed by a 1,000-patient 15-year experience.
6. Omata M, Cheng AL, Kokudo N, et al., 2017, Asia- Hepatology, 68: 1429–1440.
Pacific clinical practice guidelines on the management
of hepatocellular carcinoma: A 2017 update. Hepatol Int, https://doi.org/10.1002/hep.29691
11: 317–370. 17. Vilgrain V, Pereira H, Assenat E, et al., 2017, Efficacy and
https://doi.org/10.1007/s12072-017-9799-9 safety of selective internal radiotherapy with yttrium-90
resin microspheres compared with sorafenib in locally
7. Chow PKH, Gandhi M, Tan SB, et al., 2018, SIRveNIB: advanced and inoperable hepatocellular carcinoma
Selective internal radiation therapy versus sorafenib in Asia- (SARAH): An open-label randomised controlled phase 3
Pacific patients with hepatocellular carcinoma. J Clin Oncol, trial. Lancet Oncol, 18: 1624–1636.
36: 1913–1921.
https://doi.org/10.1016/s1470-2045(17)30683-6
https://doi.org/10.1200/jco.2017.76.0892
18. Hassanipour S, Vali M, Gaffari-Fam S, 2020, The survival
8. Kim DY, Park BJ, Kim YH, et al., 2015, Radioembolization rate of hepatocellular carcinoma in Asian countries:
with yttrium-90 resin microspheres in hepatocellular A systematic review and meta-analysis. EXCLI J, 19:
carcinoma: A multicenter prospective study. Am J Clin 108–130.
Oncol, 38: 495–501.
https://doi.org/10.17179/excli2019-1842
https://doi.org/10.1097/COC.0b013e3182a78dba
19. Llovet JM, Lencioni R, 2020, mRECIST for HCC:
9. Sangro B, Carpanese L, Cianni R, et al., 2011, Survival Performance and novel refinements. J Hepatol, 72: 288–306.
after yttrium-90 resin microsphere radioembolization of
hepatocellular carcinoma across Barcelona Clinic Liver https://doi.org/10.1016/j.jhep.2019.09.026
Cancer stages: A European evaluation. Hepatology, 54: 20. Floridi C, Pesapane F, Angileri SA, et al., 2017, Yttrium-90
868–878. radioembolization treatment for unresectable hepatocellular
https://doi.org/10.1002/hep.24451 carcinoma: A single-centre prognostic factors analysis. Med
Oncol, 34: 174.
10. Khor AY, Toh Y, Allen JC, et al., 2014, Survival and pattern
of tumor progression with yttrium-90 microsphere https://doi.org/10.1007/s12032-017-1021-3
radioembolization in predominantly hepatitis B Asian 21. Finn RS, Qin S, Ikeda M, et al., 2020, Atezolizumab plus
patients with hepatocellular carcinoma. Hepatol Int, 8: bevacizumab in unresectable hepatocellular carcinom.
395–404. N Engl J Med, 382: 1894–1905.
https://doi.org/10.1007/s12072-014-9533-9 https://doi.org/10.1056/NEJMoa1915745
11. Woo HY, Kim DY, Heo J, et al., 2017, Effect of yttrium-90 22. Bhangoo MS, Karnani DR, Hein PN, et al., 2015,
radioembolization on outcomes in Asian patients with early Radioembolization with yttrium-90 microspheres for
to advanced stage hepatocellular carcinoma. Hepatol Res, patients with unresectable hepatocellular carcinoma.
47: 387–397. J Gastrointest Oncol, 6: 469–478.
https://doi.org/10.1111/hepr.12759 https://doi.org/10.3978/j.issn.2078-6891.2015.056
12. Sirtex Medical Ply Ltd, 2019, SIR-Spheres Microspheres 23. Kallini JR, Gabr A, Thorlund K, et al., 2017, Comparison of the
[Package Insert]. Woburn, MA: Sirtex Medical Inc. adverse event profile of TheraSphere with SIR-Spheres for the
®
®
13. Lencioni R, Llovet JM, 2010, Modified RECIST (mRECIST) treatment of unresectable hepatocellular carcinoma: A systematic
assessment for hepatocellular carcinoma. Semin Liver Dis, review. Cardiovasc Intervent Radiol, 40: 1033–1043.
30: 52–60. https://doi.org/10.1007/s00270-017-1594-4

Volume 1 Issue 1 (2023) 8 https://doi.org/10.36922/arnm.0385